Drugs

PEER-REVIEWED FEATURE

Sotrovimab: Adis Evaluation

Key Points

- A recombinant human monoclonal antibody is being developed by Vir Biotechnology and GlaxoSmithKline for the treatment of COVID-19
- Received its first approval on 17 December 2021 in the EU
- Approved for the treatment of COVID-19 in adolescents (aged ≥ 12 years and weighing ≥ 40 kg) and adults who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19

Summary

Sotrovimab (Xevudy®) is a recombinant human monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus 2. It is being developed by Vir Biotechnology in collaboration with GlaxoSmithKline for the treatment of COVID-19.

Sotrovimab binds with high affinity to a highly conserved epitope of the SARS-CoV-2 spike protein receptor binding domain, thereby suppressing viremia and accelerating infected cell clearance.

On 17 December 2021, sotrovimab received its first full approval in the EU for the treatment of COVID-19 in adolescents aged ≥ 12 years and weighing ≥ 40 kg and adults who do not require oxygen supplementation and who are at high risk of progressing to severe COVID-19.

Several clinical studies of intravenous sotrovimab for the treatment of COVID-19 are currently ongoing and intramuscular administration of sotrovimab for the treatment of COVID-19 is being evaluated to increase patient access and convenience.